• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

WeightWatchers Moves Into Obesity Drug Market with Sequence Purchase

Share:

March 13, 2023

Weightwatchers announced plans to buy telehealth platform Weekend Health, also known as Sequence, in a move toward offering prescription weight loss drugs.

The company said the cash and equity transaction is valued at $132 million, but the effective net purchase price is $106 million. The deal is set to close in the second quarter this year.

Along with telehealth consultations, insurance coordination, and nutrition and fitness plans, Sequence offers glucagon-like peptide-1 medications, including semaglutide, which use the brand names Wegovy, Ozempic and Rybelsus. The company launched in 2021 and had about 24,000 members in February.

“WeightWatchers’ nutrition and behavior-change program can provide the support needed to help people build livable healthy habits for the long term and manage the dietary-induced side effects often felt while taking chronic weight management medications, such as glucagon-like peptide-1s (GLP-1s),” Dr. Gary Foster, chief scientific officer of WeightWatchers, said in a statement.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

“As we build out our clinical weight management pathway, we will be learning and likely tailoring our nutrition program for this distinct member journey. We know weight management isn’t one-size-fits-all and clinical interventions are not medically or otherwise appropriate for everyone, which is why we remain committed to all pathways.”

THE LARGER TREND

Interest and demand for semaglutide has risen in the past several months, with many pharmacists reporting shortages of Ozempic and Wegovy.

Though Ozempic is only approved to treat diabetes, there are increasing reports of off-label use for losing weight. Wegovy was first approved as a weight loss drug in 2021. Earlier this year, the American Academy of Pediatrics released new guidelines on children and obesity, arguing for early intervention, which includes surgery and medication. Wegovy was recently approved for children ages 12 and older.

Though the drug is effective, it’s also expensive. It also needs to be taken continuously or the effects will wear off.

Another digital weight loss company, Noom, has also begun offering the weight loss drugs. According to reporting by Insider, it rolled out Noom Clinical to provide some users access to GLP-1 medications.

Direct-to-consumer virtual care company Ro and another online weight loss company, Calibrate, also offer semaglutides.

Source: MobihealthNews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Amgen Successfully Completes Acquisition of Five Prime TherapeuticsAmgen Successfully Completes Acquisition of Five Prime Therapeutics
  • 3 Ways Healthcare IT Depts can Start Prepping for “Medicare for All”3 Ways Healthcare IT Depts can Start Prepping for “Medicare for All”
  • UnitedCoatings Group Announces Acquisition of CoorsTek MedicalUnitedCoatings Group Announces Acquisition of CoorsTek Medical
  • Innovaccer and Patientping Partner for Real-Time Care CoordinationInnovaccer and Patientping Partner for Real-Time Care Coordination
  • Dayton Children’s aims for Shared Savings with EHR-Powered Value-Based Care ProgramDayton Children’s aims for Shared Savings with EHR-Powered Value-Based Care Program
  • Growing Reliance On Charity, Crowd Funding To Pay For Medical Bills Means Stressed Patients, Inequities In CareGrowing Reliance On Charity, Crowd Funding To Pay For Medical Bills Means Stressed Patients, Inequities In Care
  • Catalent to Buy Paragon Bioservices for $1.2 BillionCatalent to Buy Paragon Bioservices for $1.2 Billion
  • StageBio and Tox Path Specialists MergeStageBio and Tox Path Specialists Merge

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications